OR WAIT null SECS
Developing cell-based potency assays for cell therapies requires meticulous coordination.
A single protein or gene expression product can exist in multiple proteoforms due to alternative splicing, point mutations, post translational modifications and endogenous proteolysis.
Sufficient stability studies show a drug product meets regulatory requirements, therefore ensuring the drug reaches the patients who rely on it.
March 18, 2024
In a non-exclusive licensing agreement, Ricoh will have access to ERS Genomics’ CRISPR/Cas9 genome editing technology to create novel disease models.
March 07, 2024
The agency has published final guidance documents regarding validation and development of analytical procedures.
March 01, 2024
There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.
February 06, 2024
The addition of another amino acid recognizer as well as improvements in surface chemistry, reagents, and software expand the proteome coverage of Quantum-Si’s Platinum sequencing platform.
February 02, 2024
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
February 01, 2024
Strategizing a PK/PD study approach in early phase development facilitates a successful clinical progression.
January 26, 2024
Webinar Date/Time: Thu, Feb 22, 2024 11:00 AM EST
January 16, 2024
Webinar Date/Time: Wed, Feb 28, 2024 11:00 AM EST
January 11, 2024
Webinar Date/Time: Thu, Feb 8, 2024 11:00 AM EST
January 04, 2024
Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.